U01 CA183031/CA/NCI NIH HHS/United States[Grants and Funding] - Search Results

Year	Number of Results
2015	9
2016	12
2017	9
2018	9
2019	3
2020	6
2021	3
2024	0

1

Narrative review of generative adversarial networks in medical and molecular imaging.

Koshino K, Werner RA, Pomper MG, Bundschuh RA, Toriumi F, Higuchi T, Rowe SP. Koshino K, et al. Ann Transl Med. 2021 May;9(9):821. doi: 10.21037/atm-20-6325. Ann Transl Med. 2021. PMID: 34268434 Free PMC article. Review.

2

A Systematic Review and Meta-analysis of the Effectiveness and Toxicities of Lutetium-177-labeled Prostate-specific Membrane Antigen-targeted Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer.

Sadaghiani MS, Sheikhbahaei S, Werner RA, Pienta KJ, Pomper MG, Solnes LB, Gorin MA, Wang NY, Rowe SP. Sadaghiani MS, et al. Eur Urol. 2021 Jul;80(1):82-94. doi: 10.1016/j.eururo.2021.03.004. Epub 2021 Apr 8. Eur Urol. 2021. PMID: 33840558 Free PMC article.

3

Prostate-specific membrane antigen (PSMA)-targeted photodynamic therapy enhances the delivery of PSMA-targeted magnetic nanoparticles to PSMA-expressing prostate tumors.

Ngen EJ, Chen Y, Azad BB, Boinapally S, Jacob D, Lisok A, Shen C, Hossain MS, Jin J, Bhujwalla ZM, Pomper MG, Banerjee SR. Ngen EJ, et al. Nanotheranostics. 2021 Jan 19;5(2):182-196. doi: 10.7150/ntno.52361. eCollection 2021. Nanotheranostics. 2021. PMID: 33564617 Free PMC article.

4

The prostate-specific membrane antigen (PSMA)-targeted radiotracer ¹⁸F-DCFPyL detects tumor neovasculature in metastatic, advanced, radioiodine-refractory, differentiated thyroid cancer.

Santhanam P, Russell J, Rooper LM, Ladenson PW, Pomper MG, Rowe SP. Santhanam P, et al. Med Oncol. 2020 Oct 9;37(11):98. doi: 10.1007/s12032-020-01427-0. Med Oncol. 2020. PMID: 33034761 Free PMC article.

5

Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer: The ORIOLE Phase 2 Randomized Clinical Trial.

Phillips R, Shi WY, Deek M, Radwan N, Lim SJ, Antonarakis ES, Rowe SP, Ross AE, Gorin MA, Deville C, Greco SC, Wang H, Denmeade SR, Paller CJ, Dipasquale S, DeWeese TL, Song DY, Wang H, Carducci MA, Pienta KJ, Pomper MG, Dicker AP, Eisenberger MA, Alizadeh AA, Diehn M, Tran PT. Phillips R, et al. JAMA Oncol. 2020 May 1;6(5):650-659. doi: 10.1001/jamaoncol.2020.0147. JAMA Oncol. 2020. PMID: 32215577 Free PMC article. Clinical Trial.

6

Auger radiopharmaceutical therapy targeting prostate-specific membrane antigen in a micrometastatic model of prostate cancer.

Shen CJ, Minn I, Hobbs RF, Chen Y, Josefsson A, Brummet M, Banerjee SR, Brayton CF, Mease RC, Pomper MG, Kiess AP. Shen CJ, et al. Theranostics. 2020 Feb 3;10(7):2888-2896. doi: 10.7150/thno.38882. eCollection 2020. Theranostics. 2020. PMID: 32194842 Free PMC article.

7

¹⁸F-Labeled, PSMA-Targeted Radiotracers: Leveraging the Advantages of Radiofluorination for Prostate Cancer Molecular Imaging.

Werner RA, Derlin T, Lapa C, Sheikbahaei S, Higuchi T, Giesel FL, Behr S, Drzezga A, Kimura H, Buck AK, Bengel FM, Pomper MG, Gorin MA, Rowe SP. Werner RA, et al. Theranostics. 2020 Jan 1;10(1):1-16. doi: 10.7150/thno.37894. eCollection 2020. Theranostics. 2020. PMID: 31903102 Free PMC article. Review.

8

A pilot study of prostate-specific membrane antigen (PSMA) dynamics in men undergoing treatment for advanced prostate cancer.

Paller CJ, Piana D, Eshleman JR, Riel S, Denmeade SR, Isaacsson Velho P, Rowe SP, Pomper MG, Antonarakis ES, Luo J, Eisenberger MA. Paller CJ, et al. Prostate. 2019 Oct;79(14):1597-1603. doi: 10.1002/pros.23883. Epub 2019 Jul 30. Prostate. 2019. PMID: 31361358 Free PMC article.

9

Semiquantitative Parameters in PSMA-Targeted PET Imaging with [¹⁸F]DCFPyL: Impact of Tumor Burden on Normal Organ Uptake.

Werner RA, Bundschuh RA, Bundschuh L, Lapa C, Yin Y, Javadi MS, Buck AK, Higuchi T, Pienta KJ, Pomper MG, Lodge MA, Gorin MA, Rowe SP. Werner RA, et al. Mol Imaging Biol. 2020 Feb;22(1):190-197. doi: 10.1007/s11307-019-01375-w. Mol Imaging Biol. 2020. PMID: 31140110 Free PMC article.

10

Semiquantitative Parameters in PSMA-Targeted PET Imaging with [¹⁸F]DCFPyL: Intrapatient and Interpatient Variability of Normal Organ Uptake.

Sahakyan K, Li X, Lodge MA, Werner RA, Bundschuh RA, Bundschuh L, Kulkarni HR, Schuchardt C, Baum RP, Pienta KJ, Pomper MG, Ross AE, Gorin MA, Rowe SP. Sahakyan K, et al. Mol Imaging Biol. 2020 Feb;22(1):181-189. doi: 10.1007/s11307-019-01376-9. Mol Imaging Biol. 2020. PMID: 31115751 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

42 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

42 results

Results by year